Advertisement

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Nov
04
Today In Oncology
Basser Center for BRCA Awards 2026 Global Prize
Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer
Phase III VOLGA Trial Explores Outcomes in Muscle Invasive Bladder Cancer
First-Line Pembrolizumab Improves Progression-Free Survival in dMMR Advanced Endometrial Cancer
Bispecific ADC May Offer New Treatment Option for HR-Positive, HER2-Negative Breast Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo